|
1 |
The potential of generative AI with prostate-specific membrane antigen (PSMA) PET/CT: challenges and future directions
Enthalten in Medical Review Bd. 5, 2025, Nr. 4: 265-276. 12 S.
|
|
|
2 |
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T during long-term follow-up
Hartrampf, Philipp Emanuel. - Würzburg : Universität Würzburg, 2024
|
|
|
|
3 |
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Hartrampf, Philipp E.. - Würzburg : Universität Würzburg, 2024
|
|
|
|
4 |
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
Hartrampf, Philipp E.. - Würzburg : Universität Würzburg, 2023
|
|
|
|
5 |
Interobserver agreement rates on C-X-C Motif chemokine receptor 4–directed molecular imaging and therapy
Hartrampf, Philipp E.. - Augsburg : Universität Augsburg, 2023
|
|
|
|
6 |
PSMA PET/CT
Fendler, Wolfgang. - Aachen : Universitätsbibliothek der RWTH Aachen, 2023
|
|
|
|
7 |
Red Bull PET/CT
Enthalten in Nuklearmedizin 22.12.2023
|
|
|
|
8 |
SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T
Enthalten in European journal of nuclear medicine and molecular imaging 5.6.2023: 1-10
|
|
|
|
9 |
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Enthalten in European journal of nuclear medicine and molecular imaging 5.1.2023: 1-21
|
|
|
|
10 |
[18F]DCFPyL PET/CT for imaging of prostate cancer
Rowe, Steven P.. - Augsburg : Universität Augsburg, 2022
|
|
Administration
